Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Introducing NARCAN® Nasal Spray to Dental Emergency Medical Kits

As the opioid crisis continues to spread, HealthFirst recognizes the need for dental offices to be equipped to respond to opioid overdoses. Following the recommendation of its Medical Advisory Board, HealthFirst has added NARCAN Nasal Spray to all SM Series Basic Emergency Medical Kits. This easy-to-administer drug could save a life in your practice. Harsh Reality…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from HealthFirst on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Request an invite

As the opioid crisis continues to spread, HealthFirst recognizes the need for dental offices to be equipped to respond to opioid overdoses. Following the recommendation of its Medical Advisory Board, HealthFirst has added NARCAN Nasal Spray to all SM Series Basic Emergency Medical Kits. This easy-to-administer drug could save a life in your practice.

Harsh Reality of the Opioid Epidemic

The United States Centers for Disease Control and Prevention estimates that opioid overdoses claim an average of 115 American lives each day. This class of drug, which includes painkillers, heroin, and fentanyl, has swept the nation and caused a genuine crisis.

With two million Americans addicted to pain relievers and another 591,000 struggling with heroin addiction in 2015, this epidemic has affected people across the country of all walks of life. There’s no single type of person who becomes an addict.

Why Put This Medicine in Emergency Kits?

HealthFirst has seen evidence of opioid overdoses in the dental office. Despite your best efforts to keep patients safe, you can’t control the behavior of patients or their families. As this crisis continues, dental professionals should be prepared to address overdoses with a form of naloxone, such as NARCAN.

What is NARCAN?

NARCAN Nasal Spray contains naloxone, which reverses and stops the effects of opioids. When a patient overdoses on opioids, you can quickly administer this drug to restore breathing and stop the overdosing process. In some cases, you may need to deliver subsequent doses.

While patients may experience uncomfortable withdrawal symptoms after receiving naloxone, there are no known life-threatening side effects of this drug. When weighed against the potentially fatal effects of an opioid overdose, it’s clear that naloxone is a smart option. NARCAN Nasal Spray provides an easy way to administer this life-saving medication.

HealthFirst is proud to offer dentists the basic SM Series emergency medical kit with the life-saving drug, NARCAN. Learn more about HealthFirst’s emergency kits.

Read more at healthfirst.com

HealthFirst

Part of this channel

HealthFirst

Practice-ready solutions for dental and medical offices nationwide.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.

Follow Healthcare Insights

Get new expert content in your inbox.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

OpenAI’s ChatGPT for Healthcare is getting wired into Epic

ChatGPT for Healthcare can now read from Epic. UCSF Health is piloting the read-only integration, according to Fierce Healthcare and Becker’s Hospital Review. For CIOs, the work is permissions, auditability, and clinical validation in Epic workflows.

  • 01The “read-only” label doesn’t remove governance work, it moves it to permissions mapping, audit logs, and connector scope design inside Epic-supported workflows.
  • 02OpenAI’s published clinician review results (99.1% rated safe across 4,363 ratings) are a useful benchmark, but they still need local validation on your own note templates, meds workflows, and specialty mix.

Sep 7, 2026

The EU’s MDR delay buys time, but it won’t clear your commissioning bottleneck

The European Commission backed extending EU MDR transition deadlines to December 2027 and December 2028, Medical Design & Outsourcing reported. It buys time, not ramp-up capacity. Design News cites digital commissioning and machine digital twins to cut “power-on” surprises and speed validation and operator training.

  • 01If an EU portfolio includes Class III, December 2027 is now the planning anchor, but the internal gating item may shift to validation capacity and automation readiness, not paperwork.
  • 02Digital commissioning is becoming a procurement spec, not a buzzword, because it lets teams run DFM/DFA learning loops before hardware is built, which Design News notes is meant to reduce machine power-on surprises.

Sep 5, 2026

HCA’s Q1 was not about volume. It was about coverage and collecting cash

HCA Healthcare reaffirmed 2026 guidance after Q1 weather and a muted respiratory season cut adjusted EBITDA by about $180 million, according to HealthLeaders and Fierce Healthcare. Payer mix shifted fast. Exchange admissions fell about 15% and uninsured admissions rose about 16%, Fierce reported.

  • 01A mild flu season can be a margin event: HCA tied a 42% drop in respiratory admissions to a roughly $180M adjusted EBITDA hit (HealthLeaders, Fierce Healthcare).
  • 02The 2026 risk is sliding from demand to coverage: HCA cited a $600M–$900M full-year EBITDA headwind from exchange-related changes, with $150M already in Q1 (HealthLeaders, Fierce Healthcare).
  • 03Supplemental payments are becoming an operating capability, not a windfall: HCA said Q1 Medicaid program net benefit was about $200M vs $80M expected (HealthLeaders, Fierce Healthcare), putting state-by-state reimbursement strategy on the CFO’s critical path.

Sep 5, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512